Full Text
Cardio-oncology is a rapidly evolving interdisciplinary medical specialty focused on prevention, diagnosis, monitoring, and treatment of cardiovascular complications associated with cancer and anticancer therapy. Significant progress in oncology during recent decades has resulted in substantial improvement in cancer survival rates, transforming many malignant diseases into chronic manageable conditions. As the population of long-term cancer survivors continues to increase, cardiovascular complications have become an increasingly important determinant of morbidity and mortality among oncology patients. Numerous anticancer therapies including anthracyclines, HER2-targeted agents, immune checkpoint inhibitors, tyrosine kinase inhibitors, hormonal therapy, and thoracic radiation may induce direct or indirect cardiovascular toxicity affecting the myocardium, vascular endothelium, pericardium, conduction system, and hemostatic pathways. Cardiotoxic manifestations may include left ventricular dysfunction, heart failure, arrhythmias, ischemic heart disease, hypertension, myocarditis, thromboembolic events, pulmonary hypertension, and accelerated atherosclerosis. The pathophysiological mechanisms underlying treatment-related cardiotoxicity involve oxidative stress, mitochondrial injury, endothelial dysfunction, inflammatory activation, apoptosis, fibrosis, immune dysregulation, and metabolic disturbances. Cardiovascular complications may occur during active oncological treatment or develop years after therapy completion, significantly affecting long-term survival and quality of life. Early recognition of cardiovascular risk factors and implementation of preventive cardioprotective strategies therefore play a crucial role in modern oncology practice. Advances in cardiac imaging, biomarker analysis, and individualized cardiovascular monitoring have substantially improved early detection of subclinical myocardial injury before development of irreversible cardiac dysfunction. Contemporary cardio-oncology increasingly emphasizes multidisciplinary cooperation among oncologists, cardiologists, radiologists, hematologists, and rehabilitation specialists to optimize therapeutic balance between effective cancer control and cardiovascular safety. Cardio-oncology is an evolving interdisciplinary field focused on prevention, diagnosis, monitoring, and treatment of cardiovascular complications associated with malignant disease and anticancer therapy. Rapid progress in oncology during recent decades has dramatically increased survival rates among patients with previously fatal malignancies, transforming many cancers into chronic manageable diseases. As a consequence of improved oncological survival, cardiovascular disease has emerged as one of the leading causes of morbidity and mortality among cancer survivors. Numerous antineoplastic therapies including anthracyclines, HER2-targeted agents, tyrosine kinase inhibitors, immune checkpoint inhibitors, hormonal therapies, and thoracic radiation may produce direct or indirect toxic effects on the cardiovascular system. Cardiotoxic manifestations include left ventricular dysfunction, heart failure, arrhythmias, myocarditis, ischemic heart disease, hypertension, thromboembolic complications, pulmonary hypertension, valvular abnormalities, endothelial dysfunction, and accelerated vascular aging. The mechanisms responsible for treatment-related cardiotoxicity are highly complex and involve oxidative stress, mitochondrial injury, inflammatory activation, endothelial damage, fibrosis, metabolic dysregulation, immune-mediated myocardial injury, and apoptotic cellular destruction. Cardiovascular complications may develop during active cancer therapy or appear years after treatment completion, substantially affecting long-term prognosis and quality of life. Patients with preexisting cardiovascular disease, metabolic syndrome, diabetes mellitus, obesity, dyslipidemia, and advanced age are particularly susceptible to treatment-related cardiac injury. Modern cardio-oncology therefore emphasizes early cardiovascular risk assessment before initiation of oncological treatment and continuous monitoring during therapy. Advances in echocardiography, cardiac magnetic resonance imaging, biomarker analysis, and molecular diagnostics have improved early detection of subclinical myocardial dysfunction before irreversible structural damage occurs. Contemporary management strategies increasingly rely on multidisciplinary cooperation among oncologists, cardiologists, radiologists, hematologists, rehabilitation specialists, and clinical pharmacologists to achieve optimal balance between effective cancer control and cardiovascular safety.
2. Materials and Methods
This study was conducted using retrospective and prospective clinical analysis of oncology patients receiving potentially cardiotoxic anticancer therapy between 2020 and 2025. Patients included in the study underwent comprehensive cardiovascular evaluation before initiation of oncological treatment and during follow-up observation. Clinical assessment included analysis of cardiovascular risk factors, medical history, blood pressure, metabolic profile, and baseline cardiac function. Diagnostic investigations included electrocardiography, echocardiography, cardiac magnetic resonance imaging, laboratory biomarkers including troponin and natriuretic peptides, and vascular assessment where indicated. Patients received various oncological treatments including chemotherapy, targeted biological therapy, immunotherapy, hormonal therapy, and radiation therapy. Cardiovascular complications including myocardial dysfunction, arrhythmias, hypertension, thromboembolic events, ischemic changes, and heart failure were monitored throughout treatment and post-therapy observation. Preventive cardioprotective strategies including beta-blockers, angiotensin-converting enzyme inhibitors, lifestyle modification, and individualized cardiovascular monitoring protocols were evaluated for therapeutic effectiveness. Statistical analysis was performed to determine relationships between oncological therapy type, cardiovascular risk profile, biomarker changes, and development of cardiotoxic complications.
Clinical evaluation demonstrated a significant association between anticancer therapy and development of cardiovascular complications among oncology patients. Patients receiving anthracycline-based chemotherapy and HER2-targeted therapy demonstrated higher frequency of left ventricular dysfunction, reduction of ejection fraction, and early signs of myocardial injury identified through echocardiographic and biomarker assessment. Elevated troponin and natriuretic peptide levels frequently preceded development of clinically apparent heart failure and were strongly associated with progression of subclinical cardiotoxicity. Patients with preexisting hypertension, diabetes mellitus, obesity, dyslipidemia, and advanced age exhibited significantly increased susceptibility to treatment-related cardiovascular complications. Radiation therapy involving thoracic structures contributed to vascular injury, accelerated atherosclerotic changes, valvular abnormalities, and pericardial pathology during long-term follow-up. Immune checkpoint inhibitor therapy was associated with inflammatory myocardial involvement and immune-mediated myocarditis in a smaller but clinically significant proportion of patients. Early implementation of cardioprotective treatment and individualized cardiovascular monitoring resulted in improved preservation of cardiac function and reduced incidence of severe heart failure during oncological therapy. Multidisciplinary cardio-oncology management contributed to optimization of cancer treatment continuation while minimizing cardiovascular risk and improving overall patient prognosis. Clinical and instrumental analysis demonstrated a strong association between oncological treatment and development of cardiovascular complications in patients undergoing anticancer therapy. Individuals receiving anthracycline-based chemotherapy and HER2-targeted therapy exhibited significantly higher frequency of myocardial dysfunction, reduction of left ventricular ejection fraction, and progressive impairment of cardiac contractility identified through echocardiographic and biomarker assessment. Elevated troponin and natriuretic peptide levels frequently preceded development of clinically evident heart failure and were strongly associated with subclinical cardiotoxicity during follow-up observation. Patients with preexisting hypertension, diabetes mellitus, obesity, dyslipidemia, and smoking history demonstrated greater susceptibility to treatment-related cardiovascular injury. Radiation therapy involving thoracic structures contributed to endothelial dysfunction, vascular fibrosis, accelerated atherosclerotic changes, valvular pathology, and pericardial abnormalities during long-term observation. Immune checkpoint inhibitor therapy was associated with inflammatory myocardial injury and immune-mediated myocarditis in a smaller but clinically significant proportion of patients. Early implementation of cardioprotective treatment strategies including beta-blockers, angiotensin-converting enzyme inhibitors, and individualized cardiovascular monitoring resulted in improved preservation of myocardial function and reduced progression toward symptomatic heart failure. Multidisciplinary cardio-oncology management enabled continuation of oncological therapy with lower incidence of severe cardiovascular complications and improved overall patient prognosis. Patients undergoing regular cardiovascular surveillance demonstrated earlier identification of myocardial dysfunction and better long-term functional outcomes compared with individuals receiving nonspecialized monitoring.
The findings confirm that cardio-oncology has become an essential frontier in contemporary medicine due to increasing prevalence of cardiovascular complications among cancer patients and survivors. Improvements in oncological treatment have significantly extended survival, but many patients subsequently experience cardiovascular morbidity associated with treatment-induced myocardial injury and vascular dysfunction. Cardiotoxicity mechanisms are multifactorial and involve oxidative stress, mitochondrial impairment, inflammatory activation, endothelial dysfunction, apoptosis, immune dysregulation, and progressive fibrotic remodeling of cardiac tissue. Anthracycline chemotherapy remains one of the most extensively studied causes of treatment-related cardiomyopathy, while newer targeted therapies and immunotherapies have introduced additional patterns of cardiovascular toxicity requiring specialized monitoring and management. Early detection of subclinical myocardial dysfunction through advanced imaging and biomarker analysis is critically important because timely intervention may prevent irreversible cardiac remodeling and progression toward symptomatic heart failure. The study additionally highlights the major importance of individualized cardiovascular risk stratification prior to initiation of oncological treatment. Patients with preexisting cardiovascular disease or metabolic risk factors require particularly intensive monitoring and preventive cardioprotective strategies. Contemporary cardio-oncology increasingly relies on multidisciplinary collaboration among oncologists, cardiologists, imaging specialists, pharmacists, and rehabilitation professionals to balance oncological effectiveness with cardiovascular safety. Development of standardized cardio-oncology protocols and long-term survivorship programs remains essential for improving outcomes in patients exposed to potentially cardiotoxic cancer therapies. Further research into molecular mechanisms of cardiotoxicity and development of targeted cardioprotective interventions will likely contribute to safer and more personalized oncological treatment in the future. The findings confirm that cardio-oncology has become an essential frontier of modern medicine due to increasing prevalence of cardiovascular complications among cancer patients and long-term survivors. Although advancements in oncology have significantly improved cancer-related survival, cardiovascular toxicity associated with anticancer treatment remains a major clinical challenge capable of limiting therapeutic effectiveness and reducing quality of life. The pathogenesis of treatment-related cardiotoxicity is multifactorial and involves oxidative stress-mediated myocardial injury, mitochondrial dysfunction, endothelial impairment, inflammatory activation, immune dysregulation, apoptosis, and progressive fibrotic remodeling of cardiac tissue. Anthracycline chemotherapy remains one of the most common causes of treatment-associated cardiomyopathy, while newer targeted therapies and immunotherapies introduce additional forms of cardiovascular toxicity requiring specialized diagnostic approaches and individualized management. Early detection of subclinical myocardial dysfunction is critically important because timely intervention may prevent irreversible structural remodeling and progression toward advanced heart failure. Modern imaging technologies and biomarker analysis allow identification of early cardiotoxic changes before development of clinically significant cardiac impairment. The study also highlights the importance of comprehensive cardiovascular risk stratification before initiation of cancer therapy. Patients with metabolic syndrome, hypertension, diabetes mellitus, obesity, and preexisting cardiovascular disease require intensified monitoring and preventive cardioprotective strategies throughout oncological treatment. Contemporary cardio-oncology increasingly relies on multidisciplinary collaboration involving oncologists, cardiologists, imaging specialists, pharmacists, rehabilitation professionals, and intensive care physicians to optimize balance between oncological efficacy and cardiovascular safety. Development of standardized cardio-oncology protocols and survivorship programs remains essential for reducing morbidity and mortality associated with cancer therapy–related cardiovascular complications. Further research focused on molecular mechanisms of cardiotoxicity and development of targeted cardioprotective therapies will likely improve long-term outcomes and therapeutic safety in oncology patients.
Cardio-oncology represents a rapidly expanding interdisciplinary field focused on prevention and management of cardiovascular complications associated with cancer and anticancer therapy. Modern oncological treatments significantly improve cancer survival but may induce substantial cardiotoxic effects leading to myocardial dysfunction, arrhythmias, vascular injury, and heart failure. Early cardiovascular assessment, biomarker monitoring, advanced cardiac imaging, and individualized cardioprotective intervention are essential for minimizing treatment-related cardiac complications and preserving long-term cardiac function. Multidisciplinary collaboration between cardiologists and oncologists plays a central role in optimizing therapeutic outcomes and improving quality of life among cancer patients and survivors. Continued advancement of cardio-oncology research, preventive strategies, and personalized cardiovascular monitoring remains essential for reducing morbidity and mortality associated with cancer therapy–related cardiotoxicity. Cardio-oncology represents a rapidly expanding interdisciplinary field dedicated to prevention and management of cardiovascular complications associated with malignant disease and anticancer therapy. Modern oncological treatment significantly improves cancer survival but may induce substantial cardiotoxic effects resulting in myocardial dysfunction, arrhythmias, vascular injury, and chronic heart failure. Early cardiovascular risk assessment, biomarker monitoring, advanced cardiac imaging, and individualized cardioprotective interventions play critical roles in minimizing treatment-related cardiovascular damage and preserving long-term cardiac function. Coordinated multidisciplinary cooperation between oncology and cardiology specialists substantially improves therapeutic safety, clinical outcomes, and quality of life among cancer patients and survivors. Continued advancement of cardio-oncology research, diagnostic technologies, and personalized therapeutic strategies remains essential for reducing cardiovascular morbidity and mortality associated with contemporary cancer treatment.
[1] Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229–4361.
[2] Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768–2801.
[3] Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies. Circulation. 2022;145(24):1928–1950.
[4] Curigliano G, Cardinale D, Dent S, et al. Cardiovascular toxicity induced by chemotherapy and targeted agents. Ann Oncol. 2020;31(2):171–190.
[5] Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2009;53(24):2231–2247.
[6] Lenihan DJ, Fradley MG, Dent S, et al. Proceedings from the Global Cardio-Oncology Summit. JACC CardioOncol. 2021;3(3):365–384.
[7] Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–886.
[8] Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy. J Am Soc Echocardiogr. 2014;27(9):911–939.
[9] Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers. J Clin Oncol. 2017;35(8):893–911.
[10] Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity. Circulation. 2015;131(22):1981–1988.
[11] Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32(7):831–841.
[12] Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–1467.
[13] Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503–522.
[14] Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer. Circulation. 2018;137(8):e30–e66.
[15] Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in cancer patients. Eur Heart J. 2019;40(48):3889–3897.
[16] Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics. Circulation. 2019;140(1):80–91.
[17] World Health Organization. Cancer fact sheet. Geneva: WHO; 2025.
[18] World Health Organization. Cardiovascular diseases fact sheet. Geneva: WHO; 2025.
[19] Med1.uz. Kardioonkologiya: zamonaviy tibbiyot yo‘nalishi. Available from: https://med1.uz/articles/kardiologiya/kardioonkologiya
[20] Med1.uz. Saraton terapiyasining yurakka toksik ta’siri. Available from: https://med1.uz/articles/onkologiya/kardiotoksiklik
[21] Med1.uz. Kimyoterapiya va yurak yetishmovchiligi. Available from: https://med1.uz/articles/kardiologiya/kimyoterapiya
[22] Med1.uz. Onkologik bemorlarda yurak monitoringi. Available from: https://med1.uz/articles/diagnostika/monitoring
[23] Med1.uz. Kardioonkologiyada exokardiografiya ahamiyati. Available from: https://med1.uz/articles/kardiologiya/exokardiografiya
[24] Med1.uz. Onkologik kasalliklarda yurak-qon tomir asoratlari. Available from: https://med1.uz/articles/onkologiya/asoratlar
[25] Med1.uz. Yurak-qon tomir tizimini himoya qilish strategiyalari. Available from: https://med1.uz/articles/kardiologiya/profilaktika
[26] Med1.uz. Zamonaviy onkologiyada multidissiplinar yondashuv. Available from: https://med1.uz/articles/onkologiya/multidissiplinar